挽救性淋巴结清扫治疗前列腺癌淋巴结复发:系统综述
本文系统综述了27项挽救性淋巴结清扫(SLND)系列研究,评估其在原发前列腺癌根治性治疗后仅淋巴结复发中的肿瘤学作用与安全性。SLND操作安全,3级及以上并发症率<10%,完全生化反应率13-79.5%(平均44.3%),2年及5年生化无进展生存率分别为23-64%和6-31%,5年总生存率约84%。但缺乏高级别证据,长期肿瘤学获益不确定。
要点
- SLND对影像学诊断的孤立淋巴结复发安全,3级及以上并发症率<10%。
- SLND后可获得13-79.5%的完全生化反应(平均44.3%)。
- 2年及5年生化无进展生存率分别为23-64%和6-31%,5年总生存率约84%。
核心结论
- 累积数据提示SLND是原发治疗后淋巴结复发的安全转移导向治疗选项。
- 目前仍缺乏高级别证据就SLND对长期终点的肿瘤学影响得出有临床意义的结论。
研究设计与样本
- 系统综述,遵循PRISMA指南检索PubMed和Cochrane数据库至2018年8月。
- 共纳入27项SLND系列研究进行综合。
主要发现
- 前列腺特异性膜抗原或胆碱PET/CT是参考检测技术。
- SLND通过开放或腹腔镜途径进行,3级及以上并发症率<10%。
- 平均随访29.4个月,SLND后完全生化反应率为13-79.5%(平均44.3%)。
- 2年及5年生化无进展生存率分别为23-64%和6-31%,5年总生存率约84%。
临床怎么用
- 当影像学识别出孤立淋巴结复发的前列腺癌时,针对阳性病灶的手术是安全的,可提供至少暂时的生化反应。
- SLND的肿瘤学作用需通过强临床终点进一步评估,目前尚不确定。
局限性
- 主要缺陷为单中心系列回顾性设计。
- 系列间在辅助治疗、终点、进展定义和研究人群方面存在异质性。
- 缺乏长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Identification of early nodal recurrence after primary prostate cancer (PCa) treatment by functional imaging may guide metastasis-directed therapy such as salvage lymph node dissection (SLND). OBJECTIVE: The aim of this systematic review was to assess the oncological role and the safety of SLND in the era of modern imaging in case of exclusive nodal recurrence after primary PCa treatment with curative intent. EVIDENCE ACQUISITION: A systematic literature search in the PubMed and Cochrane databases was performed up to August 2018 according to Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. Overall, 27 SLND series have been selected for synthesis. EVIDENCE SYNTHESIS: Prostate-specific membrane antigen or choline positron emission tomography/computed tomography was the reference detection technique. SLND was performed by open or laparoscopic approach with <10% of grade 3 or more complication rate. Mean follow-up was 29.4 mo. Complete biochemical response after SLND was achieved in 13-79.5%of cases (mean 44.3%). The 2- and 5-yr biochemical progression-free survival rates ranged from 23% to 64% and from 6% to 31%, respectively. Fiver-year overall survival was approximately 84%. Main drawbacks limiting the interpretation of the effectiveness of SLND were the retrospective design of single-center series, heterogeneity between series in terms of adjuvant treatment, endpoints, definitions of progression and study population, as well as the absence of long-term follow-up. CONCLUSIONS: A growing body of accumulated data suggests that SLND is a safe metastasis-directed therapy option in nodal recurrence after primary treatment. However, to date, high level of evidence is still missing to draw any clinically meaningful conclusion about the oncological impact of SLND on long-term endpoints. PATIENT SUMMARY: When imaging identifies exclusive nodal recurrent prostate cancer, surgery directed to the positive lesions is safe and can offer at least a temporary biochemical response. The oncological role assessed by strong clinical endpoints remains uncertain.
引用
- Ploussard G, Gandaglia G, Borgmann H, et al. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. Eur Urol. 2018. PMID: 30391078. doi:10.1016/j.eururo.2018.10.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。